Rashaan Z M, Krijnen P, Allema J H, Vloemans A F, Schipper I B, Breederveld R S
Department of Surgery, Leiden University Medical Center, PO Box 9600, 2333 ZA, Leiden, The Netherlands.
Burn Centre, Red Cross Hospital Beverwijk, Vondellaan 3, PO Box 1074, 1942 LE, Beverwijk, The Netherlands.
Eur J Trauma Emerg Surg. 2017 Aug;43(4):549-556. doi: 10.1007/s00068-016-0708-z. Epub 2016 Jul 18.
Evaluation of usability and effectiveness of Suprathel in the treatment of partial thickness burns in children.
A prospective, observational study to evaluate adherence of Suprathel to the wound bed, reepithelialization time, grafting, wound colonization and infection, pain, dressing changes, length of hospital stay (LOS) and scar formation.
Twenty-one children (median age 2.4 years, range 5 months-14 years) with a median total body surface area (TBSA) of 4 % (range 1-18) were included. Median LOS was 10 days (range 3-20). Median outer layer dressing changes was 3 (range 1-14). Suprathel was only adherent in wounds debrided with Versajet. Median reepithelialization time was 13 days (range 7-29). Three patients needed a split skin graft. There were 7 (33 %) patients with wound colonization before application of Suprathel. This increased to 12 (57 %) patients during treatment. One patient developed a wound infection. Median visual analog scale (VAS) scores for background and procedural pain in patients >7 years were 3.2 (range 2-5) and 3.5 (range 2-5), respectively. In younger patients, median background and procedural COMFORT-B scores were 13.8 (range 10-23) and 14.8 (range 13-23, p = 0.03), respectively. Patient and Observer Scar Assessment Scale (POSAS) scores were favorable after 3 and 6 months post burn.
Suprathel provides potential advantages regarding pain and scar formation, but extensive wound debridement is needed to achieve adequate adherence.
评估Suprathel在儿童浅度烧伤治疗中的可用性和有效性。
一项前瞻性观察性研究，以评估Suprathel与创面床的贴合度、再上皮化时间、植皮情况、创面定植和感染情况、疼痛程度、换药次数、住院时间（LOS）以及瘢痕形成情况。
纳入21名儿童（中位年龄2.4岁，范围5个月至14岁），中位总体表面积（TBSA）为4%（范围1%至18%）。中位住院时间为10天（范围3至20天）。中位外层换药次数为3次（范围1至14次）。Suprathel仅在使用Versajet清创的创面上有良好贴合。中位再上皮化时间为13天（范围7至29天）。3例患者需要进行自体皮移植。7例（33%）患者在应用Suprathel前创面有细菌定植。治疗期间这一比例增至12例（57%）。1例患者发生创面感染。7岁以上患者背景疼痛和操作疼痛的视觉模拟量表（VAS）评分中位数分别为3.2（范围2至5）和3.5（范围2至5）。在较年幼患者中，背景疼痛和操作疼痛的COMFORT - B评分中位数分别为13.8（范围10至23）和14.8（范围13至23，p = 0.03）。烧伤后3个月和6个月时，患者和观察者瘢痕评估量表（POSAS）评分结果良好。
Suprathel在疼痛和瘢痕形成方面具有潜在优势，但需要进行广泛的创面清创以实现充分贴合。
